Download Files:
BC-7013
$174 – $3,080
Products Details
Product Description
– BC-7013 is a novel semi-synthetic pleuromutilin derivative. BC-7013 has excellent activity against Gram-positive pathogenic bacteria. BC-7013 exhibits potent antibacterial properties against both Staphylococcus, Streptococcus and penicillin-resistant Streptococcus pneumoniae. BC-7013 has activity against Gram-positive pathogenic bacteria, BC-7013 is useful in the research of acute bacterial skin and skin structure infection (ABSSSI)[1].
Web ID
– HY-113640
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture and light)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C29H40O5S
References
– [1]Shang R, et al. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr Top Med Chem. 2013;13(24):3013-25.|[2]Biedenbach D J, et al. In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009, 49: 199
CAS Number
– 1028291-66-8
Molecular Weight
– 500.69
Compound Purity
– 99.04
SMILES
– O=C(CSC1=CC=CC(CO)=C1)O[C@H]2[C@]3(C)[C@@H](CC[C@]4([C@H]([C@@H]([C@](C=C)(C2)C)O)C)[C@@]3([H])C(CC4)=O)C
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Bacterial
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
